Cristi Leeberg
Adult Health · Melbourne, FLNPI 1982971404
Payments from drug & device makers
Across 16 payments — averaging $58.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Next Science LLC$224
- Corium, LLC$210
- Mimedx Group, Inc.$149
- Neurocrine Biosciences, Inc.$124
- Vanda Pharmaceuticals Inc.$123
- Acadia Pharmaceuticals Inc$56
- plus $50 from 1 others
What the payments were for
- Food & beverage$936100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Next Science LLC | 3 | $224 |
| Corium, LLC | 5 | $210 |
| Mimedx Group, Inc. | 3 | $149 |
| Neurocrine Biosciences, Inc. | 1 | $124 |
| Vanda Pharmaceuticals Inc. | 1 | $123 |
| Acadia Pharmaceuticals Inc | 1 | $56 |
| Progenacare Global, LLC | 2 | $50 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$936 in reported general payments places this provider in the 60th percentile of 2,237 adult health providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 30 | $13,741 |
| EliquisApixaban | 21 | $11,540 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $5,493 |
| Memantine Hcl | 37 | $2,415 |
| Lisdexamfetamine Dimesylate | 24 | $1,750 |
| VyvanseLisdexamfetamine Dimesylate | 16 | $1,572 |
| Memantine Hcl ErMemantine Hcl | 12 | $1,091 |
| Tramadol Hcl | 40 | $992 |
| Mirtazapine | 24 | $852 |
| Levothyroxine Sodium | 59 | $621 |
| Trazodone Hcl | 42 | $579 |
| Nebivolol Hcl | 12 | $432 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 20 | $428 |
| Gabapentin | 26 | $393 |
| Potassium Chloride | 13 | $379 |
Paid to pharmacies, not to this prescriber.
Other adult health in Melbourne
- Melissa StudebakerMelbourne$16K
- Patricia PagnottaMaitland$441K
- Carly KoelschSarasota$265K
- Norma SolisMiami$150K
- Ashley PontenbergWinter Park$136K
- Jeffrey HernandezMiami$122K
- Jamie JohnsonTampa$58K
- Jessica MangesClearwater$52K
- Sita SwamyOrlando$49K
- Alejandro Dela CruzOrlando$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.